BUSINESS SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Business Segment Information [Text Block]

BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial organizations distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Net sales of key products were as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Dollars in Millions	2013		2012		2013		2012
Virology
Baraclude (entecavir)	$	371	$	357	$	737	$	682
Reyataz (atazanavir sulfate)	431		406		792		764
Sustiva (efavirenz) Franchise	411		388		798		774
Oncology
Erbitux* (cetuximab)	171		179		333		358
Sprycel (dasatinib)	312		244		599		475
Yervoy (ipilimumab)	233		162		462		316
Neuroscience
Abilify* (aripiprazole)	563		711		1,085		1,332
Metabolics
Bydureon* (exenatide extended-release for injectable suspension)	66		N/A		118		N/A
Byetta* (exenatide)	104		N/A		189		N/A
Forxiga (dapagliflozin)	5		N/A		8		N/A
Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)	240		172		442		333
Immunoscience
Nulojix (belatacept)	6		3		11		4
Orencia (abatacept)	352		290		672		544
Cardiovascular
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)	56		117		102		324
Eliquis (apixaban)	12		1		34		1
Plavix* (clopidogrel bisulfate)	44		741		135		2,434
Mature Products and All Other	671		672		1,362		1,353
Net Sales	$	4,048	$	4,443	$	7,879	$	9,694

* Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.